BioSpace News Archive

Osmotica Pharmaceuticals plc announced that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and other key speakers, will host a call to discuss recent UPNEEQ® trends, pending expansion into the medical Aesthetics market and other general business updates as follows.

PacBio announced an expansion of its extensive suite of HiFi applications with Azenta Life Sciences, formerly GENEWIZ.

Codiak BioSciences, Inc. announced that Douglas E. Williams, Ph.D., President and CEO, and Linda C. Bain, CFO, will participate in the H.C. Wainwright Virtual BioConnect 2022 Conference, which is taking place from Monday, January 10 to Thursday, January 13.

23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced the first participant has been dosed in a Phase 1 clinical trial evaluating 23ME-00610 for the treatment of advanced solid tumors. 23ME-00610 is 23andMe’s first wholly-owned immuno-oncology (I/O) antibody to enter the clinic.

Elpiscience Biopharmaceuticals, Inc., a global clinical-stage biopharmaceutical company dedicated to discovering and developing next-generation cancer immunotherapies, announced that its co-founder and chief executive officer, Dr. Darren Ji, will present at the J.P. Morgan 40th Annual Healthcare Conference.

BIOLASE, Inc. announced the FDA 510 clearance of the EdgePRO system for endodontists seeking a more effective cleaning and disinfection alternative within root canal procedures.

Garuda Therapeutics, a company developing off-the-shelf, durable blood stem cell therapies, today announced that Dhvanit Shah, Ph.D., Co-Founder, President and Chief Executive Officer, will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022 (Tuesday) at 5:30 pm EST.

Children’s Hospital of Philadelphia appointed Alexis A. Thompson, MD as Chief of the Division of Hematology in the Department of Pediatrics, following a national search.

n-Lorem, a nonprofit foundation, today noted important new guidance recently issued by the U.S. Food and Drug Administration (FDA) regarding both the manufacturing processes and stability testing required for antisense oligonucleotides (ASOs) to be administered to nano-rare patients and the clinical administration of ASO therapeutics for nano-rare patients.

Orca Bio, a clinical-stage biotechnology company developing purified, high-precision cell therapies for the treatment of cancer, autoimmune diseases and genetic blood disorders, today announced that Ivan Dimov, Ph.D., Orca Bio’s chief executive officer and co-founder, will present at the 40th Annual J.P. Morgan Healthcare Conference.